DRUGphase3gene therapy
itvisma
Mechanism
AAV9-SMN1 gene replacement (extended label for older SMA patients) — Novartis. EMA CHMP positive opinion 2026-04-23, EC decision pending.
Related claims (0)
No claims matched “itvisma” in free-text search.
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.